Targeting key lipid metabolism enzymes (SCD, FADS2, ACLY, and ACSL) to re-sensitize cancer cells to chemotherapy has already been demonstrated as a successful approach to combat glioma and glioblastoma [62–64]. The gene discussed is FADS2; the disease is glioma.